Unitaid welcomes the recent announcement by Médecins Sans Frontières (MSF) that they have secured a price of US$ 120 for treatments for hepatitis C virus (HCV). The news is a significant milestone in the race to eliminate viral hepatitis.
MSF’s HCV project, which Unitaid has funded for the past three years, aims to improve access to diagnosis and treatment for HCV in low- and middle-income countries.
The focus is on three main areas: developing simple, adapted and cost-effective models of care so that countries can efficiently scale up HCV diagnosis and treatment; ensuring products are available at the lowest possible price; and evaluating diagnostics and treatments that work for different genetic variants of the virus.
Today’s announcement complements the broader work MSF are doing to develop models of care so that countries can scale up HCV diagnosis and treatment with maximum efficiency.
MSF’s HCV project is a critical component of Unitaid’s portfolio of co-infection grants. We are excited about the impact that is now being realized through Unitaid investment in hepatitis C.
Read more:
“MSF secures generic hepatitis C treatment at $120 compared to $147,000 launch price tag” – Médecins Sans Frontières Access campaign website
“Improving access to diagnosis and treatment for hepatitis C in low- and middle-income countries” – Unitaid project page
